Maternal–Fetal Interface-Targeted Therapies for Selective Treatment of Placental Dysfunction

Abstract

Placental dysfunction is a central mediator of adverse perinatal outcomes, including preeclampsia, fetal growth restriction, and stillbirth. Emerging therapies aimed at the maternal–fetal interface offer promise for selective management of placental disorders, targeting underlying pathophysiological processes while minimizing systemic effects. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and treatment strategies for placental dysfunction, with a focus on interface-directed modalities. Recent advances and guideline recommendations are discussed, providing clinicians with an updated and practical resource for optimizing maternal and fetal outcomes.

Introduction

Placental dysfunction encompasses a heterogeneous group of disorders resulting from impaired development or function of the placenta, disrupting maternal–fetal exchange and contributing significantly to perinatal morbidity and mortality. The maternal–fetal interface, comprising trophoblasts, decidual cells, immune elements, and vascular structures, orchestrates the complex interactions necessary for gestational success. Dysfunction at this interface has been implicated in conditions such as preeclampsia, intrauterine growth restriction (IUGR), and placental abruption. In recent years, mechanistic insights and translational advances have fostered the development of targeted therapies that selectively modulate the maternal–fetal interface, aiming to restore normal placental function and improve clinical outcomes. This review aims to provide a comprehensive overview of these evolving therapeutic strategies and their clinical implications for healthcare professionals.

Epidemiology / Disease Burden

Placental dysfunction is implicated in approximately 5–10% of pregnancies and is a leading contributor to adverse perinatal outcomes globally. Preeclampsia alone affects an estimated 2–8% of pregnancies, with higher prevalence in low-resource settings. Fetal growth restriction due to placental insufficiency is associated with increased risks of stillbirth, neonatal morbidity, and long-term cardiovascular and metabolic sequelae. The burden of disease is compounded by the lack of definitive therapies for established dysfunction, underscoring the need for effective, targeted interventions at the maternal–fetal interface.

Pathophysiology

Placental dysfunction arises from aberrant trophoblast invasion, impaired spiral artery remodeling, and maladaptation of maternal immune responses. The maternal–fetal interface is characterized by a delicate balance between immune tolerance and defense, vascular adaptation, and endocrine signaling. Disruption of these processes leads to inadequate placental perfusion, oxidative stress, and release of antiangiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and endoglin. These factors contribute to systemic endothelial dysfunction and hypertension in the mother, and to nutrient and oxygen deprivation in the fetus. Molecular studies have identified key pathways amenable to pharmacologic and biologic interventions, providing a rationale for interface-targeted therapies.

Risk Factors

Major risk factors for placental dysfunction include advanced maternal age, pre-existing hypertension, diabetes mellitus, obesity, autoimmune disorders, and a history of placental disease in prior pregnancies. Assisted reproductive technologies and multifetal gestations also confer increased risk. Genetic susceptibility and environmental exposures, such as smoking and air pollution, further modulate individual risk. Early identification of risk factors is essential for targeted surveillance and timely intervention.

Clinical Features

Placental dysfunction may manifest as maternal symptoms (e.g., hypertension, proteinuria, edema) or fetal complications (e.g., growth restriction, oligohydramnios, abnormal Dopplers). Preeclampsia is characterized by new-onset hypertension and end-organ involvement, while IUGR presents as an estimated fetal weight below the 10th percentile for gestational age. Clinical suspicion should be heightened in women with known risk factors, abnormal uterine artery Doppler studies, or atypical fetal growth patterns.

Diagnosis

Diagnosis is based on a combination of clinical, laboratory, and imaging findings. Ultrasonography is pivotal for assessing placental morphology, fetal growth, and Doppler flow in uterine and umbilical arteries. Biomarkers such as placental growth factor (PlGF), sFlt-1, and pregnancy-associated plasma protein A (PAPP-A) may aid in early detection and risk stratification. Histopathological examination of the placenta post-delivery remains the gold standard for confirming dysfunction, but is not available antepartum.

Treatment & Management

Current management is largely supportive, focusing on maternal blood pressure control, fetal surveillance, and timely delivery to prevent severe complications. Antihypertensive agents, corticosteroids for fetal lung maturity, and magnesium sulfate for seizure prophylaxis are standard interventions. However, these approaches do not directly address the underlying placental pathology. Recent efforts are directed toward therapies that target the maternal–fetal interface to restore placental function and prolong gestation.

Recent Advances / Emerging Therapies

Several promising therapies are in development or early clinical use. Angiogenic modulators, such as recombinant PlGF and neutralizing antibodies against sFlt-1, aim to correct the angiogenic imbalance underlying preeclampsia. Maternal intravenous administration of pravastatin has shown potential in reducing sFlt-1 levels and improving placental perfusion in pilot studies. Gene therapy approaches targeting trophoblast invasion and immune modulation are under investigation. Nanoparticle-mediated drug delivery systems offer the potential for localized therapy at the interface, minimizing maternal and fetal exposure. Cell-based therapies, including mesenchymal stromal cell infusions, have demonstrated immunomodulatory and proangiogenic effects in preclinical models. Ongoing trials will clarify the safety, efficacy, and feasibility of these novel interventions in clinical practice.

Guideline Recommendations

Current guidelines from the American College of Obstetricians and Gynecologists (ACOG), the International Society for the Study of Hypertension in Pregnancy (ISSHP), and other bodies emphasize risk assessment, early detection, and timely delivery as cornerstones of placental disease management. While interface-targeted therapies have not yet been incorporated into routine guidelines due to limited large-scale clinical data, several expert consensus statements support participation in clinical trials for eligible patients. Ongoing research is expected to inform future updates and facilitate translation of these therapies into standard care.

Conclusion

Placental dysfunction remains a major contributor to maternal and perinatal morbidity worldwide. Advances in understanding the maternal–fetal interface have opened new avenues for targeted therapy, with the potential to selectively restore placental function and improve outcomes. Continued research, rigorous clinical trials, and multidisciplinary collaboration are essential to translate these innovations into practice. Clinicians should remain informed of emerging evidence and consider participation in clinical studies to offer patients access to cutting-edge therapies as they become available.